Registration
CHAMBER HILL STRATEGIES for AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S.959, Pharmaceutical Quality, Security, and Accountability Act and H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; FDA issues relative to pharmacy compounding
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER BELL New | Policy Advisor, Senate Finance Committee; LA, Sen. Thune |
| ADAM ETZION New | — |
| MICHAELA SIMS New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.